IE
INAB icon

Israel Englander’s IN8bio INAB Stock Holding History

Israel Englander’s Portfolio INAB Stock Details INAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,085
Closed -$38.4K – 6201
2024
Q1 		$38.4K Buy
+1,085
New +$40.9K ﹤0.01% 5725
2021
Q4 		– Sell
-845
Closed -$175K – 7077
2021
Q3 		$175K Buy
+845
New +$210K ﹤0.01% 6191

Other funds holding INAB

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.97B AUM 32.34% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIG
Stonegate Investment Group Birmingham, Alabama $4.31B AUM 18.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

Israel Englander's INAB Position: Q2 2024 in Review

Israel Englander sold out of IN8bio (INAB) in Q2 2024, closing a stake of 1,085 shares — an estimated $38.4K sold.

Israel Englander first reported a position in INAB in Q3 2021 and held it in 2 quarters. The position peaked at $175K in Q3 2021. 26 funds tracked by Wall St. Rank hold INAB as of Q2 2024.

  • Israel Englander reported no remaining IN8bio position as of Q2 2024 after selling out during the quarter.
  • Israel Englander sold 1,085 IN8bio shares in Q2 2024, an estimated $38.4K.
  • Israel Englander first reported a position in IN8bio in Q3 2021 and held it in 2 quarters.
  • Israel Englander's IN8bio position peaked at $175K in Q3 2021.
  • 26 funds tracked by Wall St. Rank held IN8bio as of Q2 2024.

Based on Millennium Management's 13F filing for Q2 2024, filed 14 Aug 2024.